SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
Recommended by:
bodish
Olecranon
To: ghettogoulash who wrote (63168)7/18/2025 9:57:28 PM
From: ghettogoulash2 Recommendations  Read Replies (1) of 63281
 
There was a plea today on STAT news from two activist mothers of Duchenne patients. I was able to read it as a free article, but can provide the text if anyone wants it: statnews.com Excerpt:

"As parents, we have each dared to enroll our children in clinical trials whose risk/benefit calculus was still being tabulated, with questions still outstanding. Each of us has had to sign lengthy consent forms acknowledging the risks of infusing our children with experimental gene therapies (one Sarepta’s, the other an earlier candidate) in these trials — risks including liver injury, acute liver failure, and death.

Still, we made the choice to sign, because our children didn’t have extra years, months, or even days to wait for help. When you’re adrift at sea, you don’t ruminate over how the rowboat might sink; you simply climb in."


These were a few of the testimonies of treating physicians in 2023: share.google

Two years later, the physical data is becoming less ambiguous: chatgpt.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext